Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
127 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2014', provides an overview of the Retinitis Pigmentosa (Retinitis)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Retinitis Pigmentosa (Retinitis) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Retinitis Pigmentosa (Retinitis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Retinitis Pigmentosa (Retinitis) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Retinitis Pigmentosa (Retinitis) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Retinitis Pigmentosa (Retinitis) Overview 10 Therapeutics Development 11 Pipeline Products for Retinitis Pigmentosa (Retinitis) - Overview 11 Pipeline Products for Retinitis Pigmentosa (Retinitis) - Comparative Analysis 12 Retinitis Pigmentosa (Retinitis) - Therapeutics under Development by Companies 13 Retinitis Pigmentosa (Retinitis) - Therapeutics under Investigation by Universities/Institutes 15 Retinitis Pigmentosa (Retinitis) - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Retinitis Pigmentosa (Retinitis) - Products under Development by Companies 19 Retinitis Pigmentosa (Retinitis) - Products under Investigation by Universities/Institutes 21 Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development 22 Acucela Inc. 22 Amarantus Bioscience Holdings, Inc. 23 Applied Genetic Technologies Corporation 24 Asklepios BioPharmaceutical, Inc. 25 BBB Therapeutics B.V. 26 BioDiem Ltd 27 DNAVEC Corporation 28 Dompe Farmaceutici S.p.A. 29 Genable Technologies Limited 30 GenSight Biologics 31 Grupo Ferrer Internacional, S.A. 32 International Stem Cell Corporation 33 Mimetogen Pharmaceuticals Inc. 34 NeoStem, Inc. 35 Neurotech Pharmaceuticals, Inc. 36 Ocata Therapeutics, Inc. 37 Orphagen Pharmaceuticals, Inc. 38 QLT Inc. 39 R-Tech Ueno, Ltd. 40 ReGenX Biosciences, LLC 41 ReNeuron Group plc 42 Sanofi 43 Shire Plc 44 Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment 45 Assessment by Monotherapy Products 45 Assessment by Target 46 Assessment by Mechanism of Action 48 Assessment by Route of Administration 50 Assessment by Molecule Type 52 Drug Profiles 54 AMRS-001 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 BDM-E - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 BNP-RP - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 CB-11 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 emixustat hydrochloride - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 FIB-111 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Gene Therapy for Ocular Diseases - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Gene Therapy for Ophthalmology - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Gene Therapy for Retinitis Pigmentosa - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Gene Therapy for Retinitis Pigmentosa - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Gene Therapy for Retinitis Pigmentosa and Glaucoma - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 GT-038 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 KIRA-6 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 NT-501 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 PRO-015 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 proinsulin human SR - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 QLT-091001 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Recombinant Human Nerve Growth Factor - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 ReN-003 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 RST-001 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 SHP-630 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Small Molecule 5 for Retinitis Pigmentosa - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Small Molecule 9 for Retinitis Pigmentosa - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Small Molecule for Retinitis Pigmentosa - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Small Molecule to Agonize Neurotrophin Receptor for Retinitis Pigmentosa - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Small Molecules for CNS Disorders and Ophthalmology - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 Small Molecules for Inherited Retinal Diseases - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Small Molecules to Modulate Nuclear Receptors for Retinitis Pigmentosa - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Stem Cell Therapy for Age Related Macular Degeneration and Retinitis Pigmentosa - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 Stem Cell Therapy for AMD and Retinitis Pigmentosa - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 Stem Cell Therapy for Ophthalmic Disorders - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 Stem Cell Therapy for Ophthalmological Disorders - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 Stem Cell Therapy for Retinitis Pigmentosa - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Stem Cell Therapy to Activate MFRP for Retinitis Pigmentosa - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 unoprostone isopropyl - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 UshStat - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 Retinitis Pigmentosa (Retinitis) - Recent Pipeline Updates 101 Retinitis Pigmentosa (Retinitis) - Dormant Projects 118 Retinitis Pigmentosa (Retinitis) - Discontinued Products 119 Retinitis Pigmentosa (Retinitis) - Product Development Milestones 120 Featured News & Press Releases 120 Oct 30, 2014: RetroSense Therapeutics Granted Orphan Drug Designation for Lead Product RST-001 for Retinitis Pigmentosa 120 Oct 16, 2014: Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa 120 Sep 10, 2014: Amarantus to Present Orphan Ocular Data at Targeting Ocular Disorders Conference 2014 121 Sep 09, 2014: Amarantus Announces Positive MANF Ocular Toxicology Data 121 Jul 02, 2014: Amarantus Announces Positive Interim Toxicology Data for MANF in Retinitis Pigmentosa 122 Apr 25, 2014: Sucampo Pharma To Present Preclinical Data For Unoprostone Isopropyl At Experimental Biology Conference 2014 122 Apr 03, 2014: First Patient is Enrolled in Lumos Study. Objective: to Evaluate Safety and Potential Efficacy of rhNGF in the Treatment of Retinitis Pigmentosa 123 Mar 11, 2014: ReNeuron to receive support from Foundation Fighting Blindness for its retinal stem cell therapy candidate for treatment of retinitis pigmentosa 123 Feb 27, 2014: QLT Announces Positive Preliminary Results From Phase 1b Retreatment Trial of QLT091001 in Subjects With Leber Congenital Amaurosis and Retinitis Pigmentosa Due to Mutations in LRAT or RPE65 124 Feb 06, 2014: California Stem Cell Partners on CIRM Grant to Develop Transplantable 3D Retinas 125 Appendix 126 Methodology 126 Coverage 126 Secondary Research 126 Primary Research 126 Expert Panel Validation 126 Contact Us 127 Disclaimer 127
List of Tables Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2014 11 Number of Products under Development for Retinitis Pigmentosa (Retinitis) - Comparative Analysis, H2 2014 12 Number of Products under Development by Companies, H2 2014 13 Number of Products under Investigation by Universities/Institutes, H2 2014 15 Comparative Analysis by Late Stage Development, H2 2014 16 Comparative Analysis by Clinical Stage Development, H2 2014 17 Comparative Analysis by Early Stage Development, H2 2014 18 Products under Development by Companies, H2 2014 19 Products under Investigation by Universities/Institutes, H2 2014 21 Retinitis Pigmentosa (Retinitis) - Pipeline by Acucela Inc., H2 2014 22 Retinitis Pigmentosa (Retinitis) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2014 23 Retinitis Pigmentosa (Retinitis) - Pipeline by Applied Genetic Technologies Corporation, H2 2014 24 Retinitis Pigmentosa (Retinitis) - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2014 25 Retinitis Pigmentosa (Retinitis) - Pipeline by BBB Therapeutics B.V., H2 2014 26 Retinitis Pigmentosa (Retinitis) - Pipeline by BioDiem Ltd, H2 2014 27 Retinitis Pigmentosa (Retinitis) - Pipeline by DNAVEC Corporation, H2 2014 28 Retinitis Pigmentosa (Retinitis) - Pipeline by Dompe Farmaceutici S.p.A., H2 2014 29 Retinitis Pigmentosa (Retinitis) - Pipeline by Genable Technologies Limited, H2 2014 30 Retinitis Pigmentosa (Retinitis) - Pipeline by GenSight Biologics, H2 2014 31 Retinitis Pigmentosa (Retinitis) - Pipeline by Grupo Ferrer Internacional, S.A., H2 2014 32 Retinitis Pigmentosa (Retinitis) - Pipeline by International Stem Cell Corporation, H2 2014 33 Retinitis Pigmentosa (Retinitis) - Pipeline by Mimetogen Pharmaceuticals Inc., H2 2014 34 Retinitis Pigmentosa (Retinitis) - Pipeline by NeoStem, Inc., H2 2014 35 Retinitis Pigmentosa (Retinitis) - Pipeline by Neurotech Pharmaceuticals, Inc., H2 2014 36 Retinitis Pigmentosa (Retinitis) - Pipeline by Ocata Therapeutics, Inc., H2 2014 37 Retinitis Pigmentosa (Retinitis) - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2014 38 Retinitis Pigmentosa (Retinitis) - Pipeline by QLT Inc., H2 2014 39 Retinitis Pigmentosa (Retinitis) - Pipeline by R-Tech Ueno, Ltd., H2 2014 40 Retinitis Pigmentosa (Retinitis) - Pipeline by ReGenX Biosciences, LLC, H2 2014 41 Retinitis Pigmentosa (Retinitis) - Pipeline by ReNeuron Group plc, H2 2014 42 Retinitis Pigmentosa (Retinitis) - Pipeline by Sanofi, H2 2014 43 Retinitis Pigmentosa (Retinitis) - Pipeline by Shire Plc, H2 2014 44 Assessment by Monotherapy Products, H2 2014 45 Number of Products by Stage and Target, H2 2014 47 Number of Products by Stage and Mechanism of Action, H2 2014 49 Number of Products by Stage and Route of Administration, H2 2014 51 Number of Products by Stage and Molecule Type, H2 2014 53 Retinitis Pigmentosa (Retinitis) Therapeutics - Recent Pipeline Updates, H2 2014 101 Retinitis Pigmentosa (Retinitis) - Dormant Projects, H2 2014 118 Retinitis Pigmentosa (Retinitis) - Discontinued Products, H2 2014 119
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.